Most Read Articles
5 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
3 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Entecavir, tenofovir prevent HBV recurrence in liver transplant patients

21 Sep 2018

Monoprophylaxis with entecavir (ETV) or tenofovir (TDF) following a 6-month combination therapy regimen of hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogues can prevent recurrence of hepatitis B virus (HBV) infection, a recent study has shown.

Researchers followed 77 liver transplant patients, of whom 69 were infected with HBV (group A; median age 53; 80 percent male), while eight were co-infected with HBV and HDV (group B; median age 45 years; 50 percent male). Patients had been receiving HBIg for at least 6 months. After discontinuation, 54 percent were given TDF while 46 percent received ETV.

The median follow-up time after withdrawal from HBIg was 69 and 61 months for groups A and B, respectively. A total of 70 patients showed a progressive drop in serum HB antibodies titres, which reached levels <10 mIU/mL after a median of 4 months. Only seven patients in group A and one in group B had significant antibody levels throughout the study duration.

There were no reported cases of HBV reinfection. Recurrence of HBV antigens were observed in 9 percent (n=6) of group A; no such case was reported for group B.

Overall recurrence was weak, with the median time from discontinuation of HBIg being 18 months. At the time of recurrence, median serum titres for the antibodies and antigens were 0.25 mIU/mL and 0.06 IU/mL, respectively. Only one patient showed significant recurrence titres (35.2 mIU/mL).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
3 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.